Monthly
US$200
Billed every month
Sign in to subscribeAs of 16 November 2026, for Tafluprost Eye Drops, 3 applications are listed as under review at China's CDE; 2 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 1 holder.
Companies, stages and changes, with each record available on this page.
Listed in the US FDA Orange Book as ZIOPTAN (NDA 202514, THEA PHARMA INC).
Last 90 days: Accepted: 2 applications
Current coverage may be incomplete
Free: up to 3 drugs, Monday digest. Sign in with Google or an email code. No card needed.
The brand names come from the US FDA Orange Book and describe US listing records for this active ingredient. They do not indicate that products under these brand names are approved or sold in China, or that Chinese applicants are affiliated with US holders.
Orange Book source export date: 2026/11/06. Version: 2026-11-06.
Showing 1 of 1 distinct brand names.
A brand with different source forms or statuses can appear on multiple rows and in both groups. Distinct brand names are counted once globally, with a limit of five.
Verified official English dosage form: Eye Drops. Listings are grouped by the source dosage form and route; records without a clear correspondence are listed in the other group. Grouping does not establish product equivalence.
| Brand name | Applicant (source text) | Application number | Dosage form (source text) | Route (source text) | Marketing status (source text) | Approval date |
|---|---|---|---|---|---|---|
| ZIOPTAN | THEA PHARMA INC | NDA 202514 · Product no. 001 | SOLUTION/DROPS | OPHTHALMIC | HUMAN PRESCRIPTION DRUG | 2012/02/10 |
No listings in this group among the displayed brand names.
Same-form/route listings come first, followed by other forms/routes. Within each group, source prescription/OTC listings precede discontinued listings; unknown statuses are last. Each status bucket is ordered by earliest approval date, ascending: pre-1982 records first, missing dates last; ties by brand name, application number and product number. The first five distinct brands in this order are selected globally. All retained source facts for those brands are shown in their own groups; a brand spanning both groups counts once.
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.
Loaded records: 1 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Santen Pharmaceutical Co.,Ltd. | Santen Pharmaceutical Co.,Ltd.Shiga Plant | H20150423 | 2015/07/27 | 0.0015%(2.5ml:37.5μg) | Imported originator drug | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
Loaded records: 13 distinct approval numbers and 11 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| Shenyang Xing Qi Yan Yao Co., Ltd. romanized | 国药准字H20253164 | 0.0015%(0.3ml:4.5μg) | Category B | XS01EET161G010010101322 | NHSA |
| Yangtze River Pharmaceutical Group Co., Ltd | 国药准字H20243690 | 0.0015%(0.3ml:4.5μg) | Category B | XS01EET161G010010101749 | NHSA |
| Hangzhou Minsheng Pharmaceutical Co., Ltd | 国药准字H20244855 | 0.0015%(2.5ml∶37.5μg) | Category B | XS01EET161G010010104494 | NHSA |
| Zhejiang Jian Feng Pharma Co., Ltd. romanized | 国药准字H20243590 | 0.0015%(2.5ml: 37.5μg) | Category B | XS01EET161G010010104655 | NHSA |
| Hainan Si Da Pharmaceutical Co., Ltd. romanized | 国药准字H20256077 | 0.0015%(0.3ml:4.5μg) | Category B | XS01EET161G010010105816 | NHSA |
| Santen Pharmaceutical Co., Ltd. | 国药准字J20150131 | 0.0015%(2.5ml:37.5μg) | Category B | XS01EET161G010010109591 | NHSA |
| Santen Pharmaceutical Co.,Ltd. | 国药准字HJ20191024 | 0.0015%(0.3ml:4.5μg) | Category B | XS01EET161G010010178986 | NHSA |
| Chengdu Sheng Di Pharmaceuticals Co., Ltd. romanized | 国药准字H20213855 | 0.0015%(0.3ml:4.5μg) | Category B | XS01EET161G010010180435 | NHSA |
| Shaanxi Li Cai Pharma Co., Ltd. romanized | 国药准字H20244914 | 0.0015%(0.3ml:4.5μg) | Category B | XS01EET161G010010183540 | NHSA |
| Suzhou Ou Kang Wei Shi Bio Technology Co., Ltd. romanized | 国药准字H20253359 | 0.0015%(0.3ml:4.5µg) | Category B | XS01EET161G010010183562 | NHSA |
| Jiangsu An Bi Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20254564 | 0.0015%(0.3ml:4.5μg) | Category B | XS01EET161G010010183683 | NHSA |
| Hubei Min Kang Pharma Group Co., Ltd. romanized | 国药准字H20256067 | 0.0015%(0.3ml:4.5μg) | Category B | XS01EET161G010010184564 | NHSA |
| Hainan Si Da Pharmaceutical Co., Ltd. romanized | 国药准字H20256077 | 0.0015%(0.3ml:4.5μg) | Category B | XS01EET161G010010205816 | NHSA |
| Santen Pharmaceutical Co.,Ltd. | 国药准字HJ20191024 | 0.0015%(0.3ml:4.5μg) | Category B | XS01EET161G010010278986 | NHSA |
| Chengdu Sheng Di Pharmaceuticals Co., Ltd. romanized | 国药准字H20213855 | 0.0015%(0.3ml:4.5μg) | Category B | XS01EET161G010010280435 | NHSA |
| Chengdu Sheng Di Pharmaceuticals Co., Ltd. romanized | 国药准字H20213855 | 0.0015%(0.3ml:4.5μg) | Category B | XS01EET161G010010380435 | NHSA |
| Santen Pharmaceutical Co.,Ltd. | 国药准字HJ20150528 | 0.0015%(2.5ml:37.5μg) | Category B | XS01EET161G010020178986 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Loaded records: 3 filings and 3 distinct first applicants.
Generic 3
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Shandong Chen Xin Fu Dou Pharma Co., Ltd. romanized | CYHS2503857 | Generic | 2025/11/03 | Not stated by source | CDE |
| Hong Yue Technology (Hu Zhou) Co., Ltd. romanized; Hangzhou Minsheng Pharmaceutical Co., Ltd | CYHS2602797 | Generic | 2026/11/12 | Not stated by source | CDE |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | CYHS2602796 | Generic | 2026/11/12 | Not stated by source | CDE |
Loaded records: 2 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Hong Yue Technology (Hu Zhou) Co., Ltd. romanized; Hangzhou Minsheng Pharmaceutical Co., Ltd | CYHS2602797 | Generic | 2026/11/12 | Not stated by source | CDE |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | CYHS2602796 | Generic | 2026/11/12 | Not stated by source | CDE |
Non-component matches: 5 companies with A status and 1 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 他氟前列素 · No verified English name | Zhejiang Ao Xiang Pharma Co., Ltd. romanized | Y20220000747 | A | Exact ingredient | 2026/09/24 | CDE |
| 他氟前列素 · No verified English name | Jia He Gui Technology Co., Ltd. You Shi Factory romanized | Y20210000395 | A | Exact ingredient | 2024/02/08 | CDE |
| 他氟前列素 · No verified English name | Yang Zi Jiang Pharma Group Jiangsu Hai Ci Bio Pharma Co., Ltd. romanized | Y20210000367 | A | Exact ingredient | 2023/06/12 | CDE |
| 他氟前列素 · No verified English name | Zhejiang Jian Feng Pharma Co., Ltd. romanized | Y20210000093 | A | Exact ingredient | 2023/08/16 | CDE |
| 他氟前列素 · No verified English name | Zhejiang Tian Yu Pharma Co., Ltd. romanized | Y20190000507 | A | Exact ingredient | 2026/08/15 | CDE |
| 他氟前列素 · No verified English name | Xu Xiao Zi Zhu Shi Hui She romanized | Y20170001527 | I | Exact ingredient | — | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/16 06:35. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
CYHS2602797
Fact date: 2026/11/12 · Site observation date: 2026/11/13
View source ↗CYHS2602796
Fact date: 2026/11/12 · Site observation date: 2026/11/13
View source ↗Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
First index-page publication dates: 2026-10-29 to 2026-11-13; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 11/30; discovered pending details: 9. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
US$200
Billed every month
Sign in to subscribeUS$540
Billed every three months
US$180 per month
Sign in to subscribeUS$1,920
Billed every year
US$160 per month
Sign in to subscribeSeparate one-time purchase
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy
No account needed.
Covers all drugs in the loaded CDE records, not only this one: weekly acceptance counts, top-10 lists and definitions. View the latest report